Trinity Biotech plc

Equities

TRIB

US8964385046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 03:54:43 2024-02-23 pm EST 5-day change 1st Jan Change
2.4 USD +7.19% Intraday chart for Trinity Biotech plc -7.69% +11.89%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Slightly Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading But End Week Higher MT
Trinity Biotech plc Provides Revenue Guidance for the Fourth Quarter of 2023 CI
European Equities Traded in the US as American Depositary Receipts Make Modest Gains in Thursday Trading MT
ADRs Slump; Evaxion Biotech A/S Declines 32% DJ
German Inflation Cools; DAX Closes in Red on US Fed Day MT
European Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Wednesday Trading MT
Transcript : Trinity Biotech plc, Q3 2023 Earnings Call, Jan 31, 2024
Bayer, Trinity Biotech Sign LoI for Glucose Monitoring Device Rollout in China, India MT
Trinity Biotech plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Trinity Biotech plc agrred to acquire CGM Assets of Waveform Technologies, Inc. CI
European Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Trading Week Modestly Higher Monday MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Chart Trinity Biotech plc
More charts
Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot, EZ and EZ. It supplies this market with other products through its clinical chemistry business. It manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
  1. Stock
  2. Equities
  3. Stock Trinity Biotech plc - Nasdaq
  4. News Trinity Biotech plc
  5. Trinity Biotech Gets Nasdaq Notice on Noncompliance for Minimum Market Value
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer